SCHEMBL7528267

SCHEMBL7528267

CC1c2nc[nH]c2CCN1C(=O)COc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 2/20 0.57
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 2/20 0.44
KCNA5 P22460 1/20 0.44
GAA P10253 2/20 0.44
USP2 O75604 1/20 0.44
CPT1A P50416 5/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 2/20 0.44
CPT1B Q92523 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
CPT2 P23786 2/20 0.42
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7527035 0.81 AOC3 (0.50) AOC3MEN1KMT2ATDP1KCNA5
SCHEMBL20852706 0.81 AOC3 (0.50) AOC3RAB9A
SCHEMBL22915876 0.81 AOC3 (0.50) AOC3RAB9A
Trifluoroacetic Acid SCHEMBL7530824 0.80 AOC3 (0.48) AOC3MEN1KMT2AKCNA5GAA
Trifluoroacetic Acid SCHEMBL7532741 0.80 AOC3 (0.48) AOC3MEN1KMT2ATDP1KCNA5
SCHEMBL7529041 0.80 AOC3 (0.61) AOC3SMN1; SMN2NPC1RAB9A
SCHEMBL7535828 0.76 AOC3 (0.47) AOC3MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL1971938 0.73 AOC3 (1.00) AOC3MEN1KMT2AGAASMN1; SMN2
SCHEMBL7534038 0.72 AOC3 (0.49) AOC3MEN1KMT2AMAPTRAB9A
SCHEMBL16036328 0.70 RAB9A (0.43) AOC3MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020198189-A1 Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans BIOVITRUM AB (SE) 2002-12-26 US disclosed
WO-2002038153-A1 NEW USE OF 4, 5, 6, 7-TETRAHYDROIMIDAZO-[4,5-C]PYRIDINE DERIVATIVES BIOVITRUM AB (SE) 2002-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198189-A1 Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans AOC3, AOC2, AOC1 AOC3 1/4885MEN1 875/4885KMT2A 2710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.